Shares of United Therapeutics (UTHR) are down $41.40, or 13%, to $287.00 in pre-market trading after Insmed (INSM) announced positive topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder, or TPIP, administered once daily in patients with pulmonary arterial hypertension.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Liquidia price target raised to $32 from $25 at Needham
- Liquidia schedules first commercial shipment of YUTREPIA
- United Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Maintaining Market Position: United Therapeutics’ Tyvaso DPI Amidst Competition and Future Growth Prospects
- Liquidia price target raised to $23 from $20 at Wells Fargo